Pioneer transcription factors (such as ASCL1 or OTX2) capable of reprogramming cancer cells may identify novel transcriptional and proteomic profiles that could be targeted to inhibit complete transdifferentiation into a pure small cell/neuroendocrine lineage state. The gene discussed is OTX2; the disease is cancer.